Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: A randomized, multicenter phase III trial

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2602-2609

  Georgoulias, Vassilis ^a   Ardavanis, Alexandros ^b   Agelidou, Athina ^b   Agelidou, Maria ^b   Chandrinos, Vassilis ^b   Tsaroucha, Emilia ^b   Toumbis, Michael ^b   Kouroussis, Charalambos ^b   Syrigos, Konstantinos ^b   Polyzos, Aristidis ^b   Samaras, Nikolaos ^b   Papakotoulas, Pavlos ^b   Christofilakis, Charalambos ^b   Ziras, Nicolaos ^b   Alegakis, Athanasios ^b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; TAXOID;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR GROWTH; VOMITING; ADULT; AGED; DISEASE COURSE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS;

EID: 4344683671     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.11.004     Document Type: Article

References (38)

1. Ginsburg RJ, Vokes EE, Rosenzweig K: Non-small cell lung cancer, in De Vita V Jr, Hellman S, Rosenberg SR (eds): Cancer: Principles and Practice in Oncology (ed 6). Philadelphia, PA, Lippincott-Raven, 2001, pp 925-983
2. Landis SM, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
3. Lubin JM: Lung and larynx, in Cancer rates and Risks (ed 4). Bethesda, MD, National Institute of Health, National Cancer Institute, 1996, pp 158-161
4. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
5. Feigal EG, Christian M, Cheson B, et al: New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 20:185-201, 1993
6. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993
7. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized trials. BMJ 311:899-909, 1995
8. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive disease non-small-cell lung cancer: The Southwest Oncology group experience. J Clin Oncol 9:1618-1626, 1991
9. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
10. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer 70:384-387, 1994
11. Fossella FV, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12:1238-1244, 1994
12. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
13. Lira-Puerto V, Zepeda G, Mohar A, et al: Phase II trial of Taxotere (docetaxel) in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 14:382, 1995 (abstr 1995)
14. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75:968-972, 1995
15. Roszkowski K, Pluzanska A, Krzaakowski M. et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small-cell lung cancer (NSCLC). Lung Cancer 27:145-157, 2000
16. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
17. Fossella FV, DeVore R, Kerr R, et al: Randomized phase II trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
18. Georgoulias V, Androulakis N, Dimopoulos AM, et al: First-line treatment of advanced non-small cell lung cancer with docetaxel and cisplatin: A multicenter phase II study. Ann Oncol 9:331-334, 1998
19. Zalcberg J, Millward M, Bishop J, et al: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 16:1948-1953, 1998
20. Le Chevalier T, Monnier A, Douillard JY, et al: Docetaxel (Taxotere) plus cisplatin: An active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 34:2032-2036, 1998
21. Luedke DW, Einhorn L, Omura GA, et al: Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: A Southern Cancer Study Group trial. J Clin Oncol 8:886-891, 1990
22. Gridelli C, Perrone F, Palmeri S, et al: Mitomycin plus vindesine plus etoposide (MEV) versus mitomycin plus vindesine plus cisplatin (MVP) in stage IV non-small cell lung cancer: A phase III multicenter randomized trial. Ann Oncol 7:821-826, 1996
23. Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: A randomized multicentre trial. Lancet 357:1478-1484, 2001
24. Lilenbaum RC, Langenberg P, Dickersin K: Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma: A meta-analysis of response, toxicity and survival. Cancer 82:116-126, 1998
25. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
26. Hollen PJ, Gralla RJ, Kris RG, et al: Quality of life during clinical trials: Conceptual model for the Lung Cancer Symptom Score (LCSS). Support Care Cancer 2:213-222, 1994
27. Holler PJ, Gralla RJ: Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 23:53-55,1996 (2 suppl 5)
28. Altman GD: Practical statistics for medical research. London, UK. Chapman and Hall, 1991
29. Armitage P, Berry G: Statistical methods in medical research (3rd Ed). Oxford, UK, Blackwell Scientific, 1994
30. Collet D: Modelling survival data in medical research. London, UK, Chapman and Hall, 1994
31. Cox DR: The analysis of binary data. London, UK, Methuen, 1970
32. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus videsine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
33. Sederholm CJMF: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): A phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 21:291 a, 2002 (abstr 1162)
34. Lilenbaum RC, Herndon J, List M, et al: Single agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life (QOL) and cost-effectiveness. Proc Am Soc Clin Oncol 21:1a, 2002 (abstr 2)
35. Bakowski MT, Crouch JD: Chemotherapy of non-small cell lung cancer: A reappraisal and a look to the future. Cancer Treat Rev 10:159-172, 1983
36. Sweeney CJ, Zhu J, Sandler AB, et al: Outcome of patients with performance status of 2 in Eastern Cooperative Oncology Group Study G 1594: A phase III trial in patients with metastatic non-small cell carcinoma. Cancer 92:2639-2647, 2001
37. Kosmidis P, Mylonakis N, Nicolaides C, et al: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: A phase IV randomized trial. J Clin Oncol 20:3578-3585, 2002
38. Fossella F, Pereira JR, von Pawel J, et al: Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 21:3016-3024, 2003